United Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024. In the quarter to June 2026, revenue fell 1.92%, EPS grew 14.0% and free cash flow grew 58.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow UTHR
United Therapeutics Corporation (UTHR) Piotroski F-score
United Therapeutics Corporation's Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, down from 9 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | (1.00) |
| FY2024 | 9 | 4.00 |
| FY2023 | 5 | (2.00) |
| FY2022 | 7 | 1.00 |
| FY2021 | 6 | 0.00 |
| FY2020 | 6 | 5.00 |
| FY2019 | 1 | (6.00) |
| FY2018 | 7 | 4.00 |
| FY2017 | 3 | (3.00) |
| FY2016 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 17.51% | 16.45% | Pass | 1 |
| Positive operating cash flow | 1.56b | 1.33b | Pass | 1 |
| Rising return on assets | 17.51% | 16.45% | Pass | 1 |
| Cash flow above net income | 226.50m | 132.00m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 6.60 | 5.25 | Pass | 1 |
| No new shares issued | 44,300,000 | 45,200,000 | Pass | 1 |
| Rising gross margin | 87.92% | 89.24% | Fail | 0 |
| Rising asset turnover | 0.42 | 0.40 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| UTHR United Therapeutics Corporation | 8 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 8 |
| HLN Haleon PLC Sponsored ADR compare | 8 |
| ZTS Zoetis Inc. compare | 7 |
| NBIX Neurocrine Biosciences, Inc. compare | 7 |
| ELAN Elanco Animal Health Incorporated compare | 5 |
| RDY Dr. Reddy's Laboratories Ltd compare | 4 |
| TAK Takeda Pharmaceutical Co. compare | 4 |
| VTRS Viatris Inc. compare | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover